| Literature DB >> 32251301 |
Dilek Colak1, Olfat Al-Harazi2, Osama M Mustafa2, Fanwei Meng3,4, Abdullah M Assiri4,5,6, Dipok K Dhar7,8,9, Dieter C Broering3,6.
Abstract
The liver is a unique organ that has a phenomenal capacity to regenerate after injury. Different surgical procedures, including partial hepatectomy (PH), intraoperative portal vein ligation (PVL), and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) show clinically distinct recovery patterns and regeneration. The observable clinical differences likely mirror some underlying variations in the patterns of gene activation and regeneration pathways. In this study, we provided a comprehensive comparative transcriptomic analysis of gene regulation in regenerating rat livers temporally spaced at 24 h and 96 h after PH, PVL, and ALPPS. The time-dependent factors appear to be the most important determinant of post-injury alterations of gene expression in liver regeneration. Gene expression profile after ALPPS showed more similar expression pattern to the PH than the PVL at the early phase of the regeneration. Early transcriptomic changes and predicted upstream regulators that were found in all three procedures included cell cycle associated genes (E2F1, CCND1, FOXM1, TP53, and RB1), transcription factors (Myc, E2F1, TBX2, FOXM1), DNA replication regulators (CDKN1A, EZH2, RRM2), G1/S-transition regulators (CCNB1, CCND1, RABL6), cytokines and growth factors (CSF2, IL-6, TNF, HGF, VEGF, and EGF), ATM and p53 signaling pathways. The functional pathway, upstream, and network analyses revealed both unique and overlapping molecular mechanisms and pathways for each surgical procedure. Identification of molecular signatures and regenerative signaling pathways for each surgical procedure further our understanding of key regulators of liver regeneration as well as patient populations that are likely to benefit from each procedure.Entities:
Mesh:
Year: 2020 PMID: 32251301 PMCID: PMC7089998 DOI: 10.1038/s41598-020-61826-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(a) Venn diagrams representing the differentially expressed genes specific or common among ALPPS, PH and PVL at 24 h and 96 h, respectively. (b) Sources of variation in the data matrix. The x-axis shows the components of the 2-way ANOVA model and the y-axis shows the mean signal to noise ratio. (c) Unsupervised PCA analysis. Different colors indicate different surgical types and shapes indicate different time points. (d) Two-dimensional hierarchical clustering of genes, that are significant in at least one surgical procedure (with respect to sham group) at any of the two time points, and samples. The figure shows the most associated GO biological processes for each cluster of genes. Red and green denote highly and weakly expressed genes, respectively.
Figure 2Bar chart of the most significant GO biological processes that are associated with up- and down-regulated genes for each surgical procedure at 24h (a) and 96h (b). X-axis represents the statistical significance of the enrichment (–log10(p-value)). Color-coding represents different surgical types.
GO Biological Processes that are enriched in DEGs in ALPPS, PVL and PH.
| GO Biological Process Term | 24 hours | 96 hours | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALPPS | PVL | PH | ALPPS | PVL | PH | |||||||
| FE* | p-value | FE* | p-value | FE* | p-value | FE* | p-value | FE* | p-value | FE* | p-value | |
| DNA metabolic process | 4.7 | 7.0E-21 | 5.8 | 8.8E-24 | 3.3 | 3.8E-17 | 1.6 | 3.3E-02 | — | — | — | — |
| cell cycle | 3.0 | 6.3E-19 | 3.8 | 1.7E-23 | 2.5 | 1.3E-18 | 1.9 | 2.4E-05 | — | — | — | — |
| DNA replication | 6.9 | 2.0E-18 | 9.2 | 1.7E-22 | 4.5 | 1.4E-14 | 2.6 | 2.0E-03 | — | — | — | — |
| chromosome segregation | 7.3 | 1.5E-13 | 8.9 | 2.5E-14 | 5.4 | 1.6E-13 | 3.4 | 5.8E-04 | — | — | 2.7 | 2.4E-02 |
| DNA repair | 5.0 | 2.1E-11 | 6.2 | 1.1E-12 | 3.3 | 1.8E-08 | – | – | — | — | — | — |
| mitosis | 3.4 | 1.3E-10 | 4.4 | 4.6E-13 | 2.8 | 5.6E-11 | 2.1 | 9.3E-04 | — | — | — | — |
| catabolic process | 2.2 | 2.1E-07 | 2.3 | 1.4E-06 | 1.7 | 1.5E-05 | 1.8 | 2.5E-04 | — | — | — | — |
| cellular process | 1.2 | 9.6E-07 | 1.2 | 4.1E-06 | 1.1 | 6.6E-03 | 1.2 | 1.7E-04 | — | — | 1.3 | 2.1E-07 |
| ion transport | 2.2 | 3.5E-04 | — | — | 1.6 | 5.0E-03 | 2.4 | 5.0E-05 | — | — | — | — |
| cytokinesis | 2.9 | 2.7E-03 | 3.2 | 4.5E-03 | 2.0 | 1.9E-02 | 2.4 | 2.2E-02 | — | — | — | — |
| metabolic process | 1.2 | 6.1E-06 | 1.3 | 1.7E-06 | 1.2 | 6.3E-07 | – | – | — | — | — | — |
| cellular component movement | 2.6 | 3.4E-06 | 2.5 | 6.1E-05 | 1.9 | 8.0E-05 | 2.1 | 6.3E-04 | — | — | 2.7 | 2.9E-05 |
| lipid metabolic process | 1.6 | 1.6E-02 | — | — | 2.6 | 2.8E-13 | 2.1 | 3.2E-05 | — | — | 2.3 | 1.1E-04 |
| response to stress | 1.6 | 2.2E-03 | 1.7 | 1.1E-03 | 1.4 | 6.1E-03 | — | — | — | — | 1.5 | 1.9E-02 |
| anion transport | 2.3 | 1.7E-03 | — | — | 1.7 | 1.4E-02 | 2.9 | 2.6E-05 | — | — | — | — |
| cellular component morphogenesis | 2.0 | 1.3E-04 | 1.7 | 1.1E-02 | — | — | 2.3 | 8.7E-06 | 3.1 | 8.7E-05 | 2.3 | 2.6E-04 |
| macrophage activation | — | — | — | — | — | — | 3.7 | 8.1E-05 | 3.5 | 3.0E-02 | 3.4 | 3.0E-03 |
| system development | — | — | — | — | — | — | 1.6 | 9.5E-04 | 1.8 | 1.5E-02 | 1.7 | 2.4E-03 |
| immune system process | — | — | — | — | — | — | 1.4 | 1.2E-02 | — | — | 2.2 | 2.3E-08 |
| developmental process | — | — | — | — | — | — | 1.3 | 1.5E-02 | — | — | 1.7 | 6.1E-05 |
| cell proliferation | — | — | — | — | — | — | 2.2 | 2.6E-02 | — | — | 6.1 | 6.1E-09 |
| signal transduction | — | — | — | — | — | — | – | – | — | — | 1.7 | 5.5E-07 |
| cell communication | — | — | — | — | — | — | – | – | — | — | 1.6 | 1.7E-06 |
| cell adhesion | — | — | — | — | — | — | 2 | 6.5E-04 | — | — | 2.6 | 1.2E-05 |
Abbreviations: DEG, differentially expressed gene; FE, Fold Enrichment is the number of DEGs involved in each GO biological process term divided by the expected number. – Denotes non-significant term.
Figure 3Gene interaction network, functional, and canonical pathway analyses (a–c, respectively) at 24h and (d–f, respectively) at 96h of common DEGs among ALPPS, PH and PVL. Red and green denote up- and down-regulated genes, respectively, and grey indicates direct interactors of the DEGs. The sizes of nodes (in a) are proportional to their betweenness centrality values[22]. Straight and dashed lines (in d) represent direct or indirect gene to gene interactions, respectively. The color intensity is correlated with fold change. X-axis (in bar graphs) indicates the significance (–log10(p-value)) of the functional/pathway association. The threshold line represents a P value of 0.05.The network (in d) and functional/pathway analyses were generated using IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).
Significantly altered canonical pathways, molecular and cellular functions, and predicted upstream regulators associated with DEGs in ALPPS, PVL and PH at 24 h and 96 h.
| ALPPS at 24 hr | ALPPS at 96 hr | ||||
|---|---|---|---|---|---|
| Canonical Pathways | p-value | Overlap | Canonical Pathways | p-value | Overlap |
| Cell Cycle Control of Chromosomal Replication | 1.51E-14 | 51.9% 14/27 | LPS/IL-1 Mediated Inhibition of RXR Function | 8.00E-06 | 9.5% 21/221 |
| Mitotic Roles of Polo-Like Kinase | 1.07E-14 | 30.3% 20/66 | Mitotic Roles of Polo-Like Kinase | 6.53E-06 | 16.7% 11/66 |
| Role of BRCA1 in DNA Damage Response | 3.84E-12 | 24.4% 19/78 | FXR/RXR Activation | 1.10E-05 | 11.9% 15/126 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.37E-12 | 32.7% 16/49 | Hepatic Fibrosis / Hepatic Stellate Cell Activation | 2.47E-04 | 8.7% 16/183 |
| E2F1 | 4.93E-41 | Activated | ERBB2 | 4.36E-22 | Activated |
| CCND1 | 2.35E-40 | Activated | TGFB1 | 5.96E-22 | Activated |
| RABL6 | 6.32E-38 | Activated | VEGF | 8.37E-21 | Activated |
| CDKN1A | 2.73E-57 | Inhibited | CSF2 | 7.02E-16 | Activated |
| TP53 | 6.98E-53 | Inhibited | CDKN1A | 3.22E-24 | Inhibited |
| Cell Cycle | 2.22E-05 - 5.88E-29 | 209 | Cell Death and Survival | 4.43E-04 - 4.11E-16 | 257 |
| Cellular Assembly and Organization | 2.88E-05 - 6.87E-26 | 186 | Cell Cycle | 4.19E-04 - 4.78E-15 | 135 |
| DNA Replication, Recombination, and Repair | 2.22E-05 - 6.87E-26 | 173 | Cellular Assembly and Organization | 4.64E-04 - 4.78E-15 | 176 |
| Cell Death and Survival | 2.88E-05 - 1.12E-18 | 278 | DNA Replication, Recombination, and Repair | 4.19E-04 - 4.78E-15 | 107 |
| Cell Morphology | 2.88E-05 - 4.40E-15 | 145 | Cellular Growth and Proliferation | 4.61E-04 - 3.22E-15 | 287 |
| Organismal Development | 1.15E-06 - 4.56E-09 | 19 | Cardiovascular System Development and Function | 2.79E-04 - 5.36E-09 | 119 |
| Connective Tissue Development and Function | 1.74E-05 - 1.02E-10 | 92 | Tissue Development | 3.41E-04 - 6.93E-09 | 211 |
| Tissue Development | 2.30E-05 - 5.37E-10 | 106 | Immune Cell Trafficking | 2.77E-04 - 1.04E-08 | 85 |
| Tissue Morphology | 2.22E-05 - 4.56E-09 | 30 | Hematological System Development and Function | 2.77E-04 - 3.13E-08 | 112 |
| Embryonic Development | 1.15E-06 - 4.56E-09 | 19 | Organismal Development | 3.38E-04 - 9.93E-08 | 128 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 3.86E-12 | 30.8% 16/52 | Renal Necrosis/Cell Death | 2.36E-07 | 7.7% 40/519 |
| Liver Proliferation | 4.84E-06 | 9.6% 22/228 | LPS/IL-1 Mediated Inhibition of RXR Function | 1.49E-07 | 10.3% 26/253 |
| Aryl Hydrocarbon Receptor Signaling | 9.04E-07 | 11.9% 19/159 | FXR/RXR Activation | 1.10E-05 | 11.9% 15/126 |
| CAR/RXR Activation | 2.58E-06 | 27.6% 8/29 | Cardiac Hypertrophy | 1.39E-06 | 7.8% 34/435 |
| Cell Cycle Control of Chromosomal Replication | 3.16E-16 | 51.9% 14/27 | GADD45 Signaling | 9.30E-04 | 15.8% 3/19 |
| Mitotic Roles of Polo-Like Kinase | 9.19E-16 | 28.8% 19/66 | Purine Ribonucleosides Degradation to Ribose-1-phosphate | 2.85E-03 | 25.0% 2/8 |
| Role of BRCA1 in DNA Damage Response | 3.60E-13 | 23.1% 18/78 | GDP-glucose Biosynthesis | 3.64E-03 | 22.2% 2/9 |
| Estrogen-mediated S-phase Entry | 2.95E-12 | 45.8% 11/24 | Glucose and Glucose-1-phosphate Degradation | 4.52E-03 | 20.0% 2/10 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 3.67E-13 | 30.6% 15/49 | Mitotic Roles of Polo-Like Kinase | 4.83E-03 | 6.1% 4/66 |
| E2F1 | 6.82E-48 | Activated | TGFB1 | 7.66E-11 | Activated |
| RABL6 | 1.67E-42 | Activated | CSF2 | 1.20E-07 | Activated |
| CCND1 | 2.68E-41 | Activated | IL4 | 3.51E-06 | Activated |
| CDKN1A | 9.47E-67 | Inhibited | SMARCA4 | 5.42E-06 | Activated |
| TP53 | 1.14E-63 | Inhibited | MYCN | 8.83E-04 | Inhibited |
| Cell Cycle | 1.57E-05 - 4.47E-38 | 202 | Cell Death and Survival | 9.04E-03 - 1.69E-09 | 96 |
| Cellular Assembly and Organization | 1.48E-05 - 3.39E-34 | 163 | Cellular Growth and Proliferation | 8.25E-03 - 3.76E-09 | 106 |
| DNA Replication, Recombination, and Repair | 1.43E-05 - 3.39E-34 | 160 | Cellular Assembly and Organization | 8.66E-03 - 3.93E-07 | 62 |
| Cell Death and Survival | 1.47E-05 - 5.70E-21 | 224 | Cell Morphology | 9.04E-03 - 7.52E-07 | 67 |
| Cell Morphology | 1.44E-05 - 5.49E-17 | 107 | Cell-To-Cell Signaling and Interaction | 8.89E-03 - 1.32E-06 | 44 |
| Reproductive System Development and Function | 1.43E-05 - 9.48E-12 | 52 | Tissue Development | 8.89E-03 - 3.93E-07 | 92 |
| Organismal Development | 6.34E-09 - 4.28E-11 | 19 | Lymphoid Tissue Structure and Development | 8.18E-03 - 4.34E-06 | 35 |
| Connective Tissue Development and Function | 1.07E-05 - 8.94E-11 | 81 | Organ Morphology | 8.89E-03 - 4.34E-06 | 38 |
| Tissue Morphology | 5.72E-06 - 4.28E-11 | 50 | Cardiovascular System Development and Function | 7.67E-03 - 1.32E-06 | 47 |
| Embryonic Development | 1.14E-05 - 4.28E-11 | 34 | Tissue Morphology | 8.46E-03 - 4.34E-06 | 65 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 9.76E-13 | 28.8% 15/52 | Nongenotoxic Hepatocarcinogenicity Biomarker Panel | 6.98E-05 | 18.2% 4/22 |
| Increases Liver Hyperplasia/Hyperproliferation | 1.29E-06 | 12.6% 13/103 | Recovery from Ischemic Acute Renal Failure (Rat) | 3.63E-04 | 21.4% 3/14 |
| Aryl Hydrocarbon Receptor Signaling | 6.67E-08 | 11.3% 18/159 | Cardiac Hypertrophy | 6.20E-04 | 3.0% 13/435 |
| Cell Cycle: G1/S Checkpoint Regulation | 5.04E-07 | 16.7% 11/66 | Increases Renal Damage | 1.52E-03 | 6.2% 5/81 |
| Cell Cycle Control of Chromosomal Replication | 2.21E-15 | 63.0% 17/27 | Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 5.40E-09 | 10.4% 20/193 |
| Role of BRCA1 in DNA Damage Response | 2.90E-12 | 30.8% 24/78 | LXR/RXR Activation | 5.62E-09 | 13.2% 16/121 |
| Mitotic Roles of Polo-Like Kinase | 3.83E-12 | 33.3% 22/66 | Acute Phase Response Signaling | 1.18E-07 | 10.1% 17/169 |
| Hereditary Breast Cancer Signaling | 4.47E-11 | 21.8% 31/142 | Phagosome Formation | 1.08E-05 | 9.8% 12/122 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 5.42E-11 | 36.7% 18/49 | Fc Receptor-mediated Phagocytosis in Macrophages and Monocytes | 2.70E-05 | 10.8% 10/93 |
| CCND1 | 4.01E-37 | Activated | TNF | 4.33E-30 | Activated |
| E2F1 | 5.13E-34 | Activated | IFNG | 2.25E-22 | Activated |
| RABL6 | 1.42E-33 | Activated | TP53 | 1.60E-21 | Activated |
| CDKN1A | 2.64E-47 | Inhibited | IL6 | 6.78E-20 | Activated |
| TP53 | 7.48E-47 | Inhibited | IL1B | 4.93E-19 | Activated |
| Cell Cycle | 6.16E-05 - 1.88E-28 | 281 | Cellular Movement | 8.64E-06 - 1.06E-28 | 161 |
| Cellular Assembly and Organization | 6.85E-05 - 1.88E-28 | 163 | Cellular Growth and Proliferation | 1.01E-05 - 2.44E-24 | 228 |
| DNA Replication, Recombination, and Repair | 6.85E-05 - 1.88E-28 | 243 | Cell Death and Survival | 9.36E-06 - 3.12E-23 | 201 |
| Cell Death and Survival | 7.54E-05 - 6.73E-17 | 420 | Cell-To-Cell Signaling and Interaction | 7.47E-06 - 4.76E-20 | 133 |
| Cell Morphology | 1.58E-05 - 4.68E-15 | 229 | Cellular Function and Maintenance | 6.05E-06 - 4.83E-17 | 187 |
| Organismal Survival | 1.95E-06 - 3.67E-09 | 292 | Hematological System Development and Function | 9.36E-06 - 1.66E-27 | 177 |
| Reproductive System Development and Function | 3.04E-05 - 3.16E-10 | 27 | Immune Cell Trafficking | 8.64E-06 - 4.34E-28 | 120 |
| Connective Tissue Development and Function | 5.16E-05 - 8.45E-11 | 132 | Cardiovascular System Development and Function | 9.16E-06 - 2.79E-19 | 120 |
| Tissue Development | 6.77E-05 - 8.45E-11 | 117 | Organismal Development | 7.85E-06 - 5.64E-17 | 154 |
| Embryonic Development | 7.74E-06 - 3.42E-07 | 27 | Tissue Morphology | 9.16E-06 - 8.60E-20 | 158 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.71E-10 | 34.6% 18/52 | Positive Acute Phase Response Proteins | 3.28E-10 | 33.3% 10/30 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 2.44E-09 | 15.8% 40/253 | LXR/RXR Activation | 7.16E-09 | 13.0% 16/123 |
| Fatty Acid Metabolism | 5.33E-09 | 21.4% 25/117 | Cardiac Necrosis/Cell Death | 1.60E-06 | 7.3% 20/273 |
| Aryl Hydrocarbon Receptor Signaling | 1.51E-08 | 18.2% 29/159 | Cardiac Hypertrophy | 6.76E-07 | 6.2% 27/435 |
| Xenobiotic Metabolism Signaling | 2.97E-06 | 11.9% 42/352 | Acute Renal Failure Panel (Rat) | 5.80E-06 | 14.5% 9/62 |
Significantly altered pathways in ALPPS, PVL and PH at 24 h and 96 h post operation.
| ALPPS at 24 hr | ALPPS at 96 hr | ||||||
|---|---|---|---|---|---|---|---|
| PANTHER Pathways | DEGs | FE | P-value | PANTHER Pathways | DEGs | FE | P-value |
| Proline biosynthesis | 2 | 16.6 | 6.7E-03 | N-acetylglucosamine metabolism | 3 | 16.8 | 8.3E-04 |
| De novo pyrimidine deoxyribonucleotide biosynthesis | 6 | 15.3 | 3.5E-06 | Adenine and hypoxanthine salvage pathway | 3 | 12.6 | 1.9E-03 |
| Formyltetrahydroformate biosynthesis | 3 | 14.2 | 1.3E-03 | Pyruvate metabolism | 5 | 9.9 | 1.8E-04 |
| DNA replication | 11 | 7.9 | 2.4E-07 | Formyltetrahydroformate biosynthesis | 2 | 9.6 | 1.9E-02 |
| Plasminogen activating cascade | 3 | 5.9 | 1.5E-02 | 5-Hydroxytryptamine degredation | 3 | 4.8 | 2.6E-02 |
| Cell cycle | 4 | 5.3 | 7.3E-03 | Axon guidance mediated by semaphorins | 3 | 4.2 | 3.6E-02 |
| Cytoskeletal regulation by Rho GTPase | 10 | 4.0 | 2.7E-04 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | 13 | 3.6 | 9.5E-05 |
| Blood coagulation | 5 | 3.5 | 1.5E-02 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | 4 | 3.2 | 3.8E-02 |
| p53 pathway | 12 | 3.2 | 5.6E-04 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | 12 | 2.5 | 4.2E-03 |
| p53 pathway feedback loops 2 | 5 | 2.8 | 3.7E-02 | Alzheimer disease-presenilin pathway | 9 | 2.3 | 2.1E-02 |
| Alzheimer disease-presenilin pathway | 11 | 2.7 | 2.9E-03 | Integrin signalling pathway | 13 | 2.2 | 7.5E-03 |
| Formyltetrahydroformate biosynthesis | 3 | 19.1 | 5.7E-04 | p53 pathway | 4 | 3.3 | 3.6E-02 |
| De novo pyrimidine deoxyribonucleotide biosynthesis | 5 | 17.2 | 1.4E-05 | Axon guidance mediated by semaphorins | 2 | 8.6 | 2.3E-02 |
| Phenylethylamine degradation | 2 | 12.8 | 1.1E-02 | Beta3 adrenergic receptor signaling pathway | 2 | 7.1 | 3.3E-02 |
| DNA replication | 11 | 10.7 | 1.3E-08 | Opioid prodynorphin pathway | 2 | 6.2 | 4.2E-02 |
| Cell cycle | 4 | 7.1 | 2.6E-03 | Cortocotropin releasing factor receptor signaling pathway | 2 | 6.2 | 4.2E-02 |
| p53 pathway feedback loops 2 | 7 | 5.2 | 4.8E-04 | Opioid proopiomelanocortin pathway | 2 | 6.1 | 4.4E-02 |
| De novo purine biosynthesis | 3 | 4.6 | 2.8E-02 | Opioid proenkephalin pathway | 2 | 6.1 | 4.4E-02 |
| p53 pathway | 11 | 3.9 | 1.7E-04 | 5HT4 type receptor mediated signaling pathway | 2 | 6.1 | 4.4E-02 |
| Blood coagulation | 4 | 3.8 | 2.2E-02 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | 4 | 3.4 | 3.1E-02 |
| Cytoskeletal regulation by Rho GTPase | 5 | 2.7 | 4.1E-02 | ||||
| Proline biosynthesis | 3 | 14.3 | 1.3E-03 | N-acetylglucosamine metabolism | 3 | 25.1 | 2.6E-04 |
| Phenylethylamine degradation | 3 | 8.1 | 6.3E-03 | Pyruvate metabolism | 4 | 11.8 | 4.1E-04 |
| Formyltetrahydroformate biosynthesis | 3 | 8.1 | 6.3E-03 | Plasminogen activating cascade | 3 | 8.9 | 5.0E-03 |
| Vitamin B6 metabolism | 2 | 7.6 | 2.9E-02 | Axon guidance mediated by semaphorins | 4 | 8.4 | 1.5E-03 |
| Salvage pyrimidine deoxyribonucleotides | 2 | 7.6 | 2.9E-02 | Blood coagulation | 5 | 5.4 | 2.7E-03 |
| De novo pyrimidine deoxyribonucleotide biosynthesis | 5 | 7.3 | 7.1E-04 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | 11 | 4.6 | 4.1E-05 |
| DNA replication | 16 | 6.6 | 6.5E-09 | Enkephalin release | 3 | 4.2 | 3.6E-02 |
| Pyruvate metabolism | 4 | 4.5 | 1.3E-02 | Ras Pathway | 6 | 3.8 | 5.8E-03 |
| Androgen/estrogene/progesterone biosynthesis | 3 | 4.1 | 3.9E-02 | VEGF signaling pathway | 5 | 3.3 | 1.9E-02 |
| Cell cycle | 5 | 3.8 | 1.1E-02 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | 10 | 3.1 | 1.9E-03 |
| Blood coagulation | 9 | 3.6 | 1.1E-03 | Interleukin signaling pathway | 6 | 3.1 | 1.5E-02 |
| 5-Hydroxytryptamine degredation | 4 | 3.6 | 2.6E-02 | Cytoskeletal regulation by Rho GTPase | 5 | 3.0 | 2.6E-02 |
| Cytoskeletal regulation by Rho GTPase | 12 | 2.8 | 1.9E-03 | Angiogenesis | 10 | 2.8 | 3.9E-03 |
| p53 pathway feedback loops 2 | 8 | 2.5 | 1.6E-02 | PDGF signaling pathway | 8 | 2.7 | 1.1E-02 |
| p53 pathway | 15 | 2.3 | 3.5E-03 | CCKR signaling map | 9 | 2.6 | 9.6E-03 |
| T cell activation | 5 | 2.5 | 5.0E-02 | ||||
| Inflammation mediated by chemokine and cytokine signaling pathway | 13 | 2.5 | 2.4E-03 | ||||
Abbreviations: DEGs, number of differentially expressed genes with respect to Sham; FE, Fold Enrichment is the number of DEGs involved in each pathway divided by the expected number.
Figure 4The upstream regulator analyses. (a) Venn diagrams representing the overlap of predicted upstream regulators that are unique or common among ALPPS, PH and PVL at 24 h (top) and 96 h (bottom). (b,c) Inter-procedural variations at 24 h and 96 h, respectively. (d–f) Temporal variations after ALPPS, PH and PVL, respectively. Heatmaps for union of top 15 activated upstream regulators in ALPPS, PVL and PH at 24 h and 96 h are used. Color scale shows significance by –log10(p-value). (g) Heatmap that displays surgical procedure as well as temporal changes for the top 50 activated/inhibited upstream regulators. The upstream regulators are ordered according to significance in ALPPS procedure. The color-key is for the z-score. Data were analyzed through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).
Figure 5Mechanistic networks of upstream regulators and their predicted relationship by IPA®. The networks for top upstream regulators: E2F1, HGF and TP53 at 24 h and TGFB1, Vegf, and TP53 at 96 h are shown.